Indian giant Ranbaxy plans to invest over 20 million dollars in the next two years in local producer Terapia, which it acquired last year following a 324 million-dollar (270 million-euro) transaction. This is one of the biggest post-acquisition investments made on the local pharmaceutical market. "When we started the due diligence process for Terapia, we took on investment commitments in order to develop the business. Last year, we invested around 10 million dollars (8 million euros), and this year we set out to reach a similar figure. Also, things do not end with the acquisition of a company," Peter Burema, president of Ranbaxy's global pharmaceutical division told ZIARUL FINANCIAR in an interview. The money will go towards reorganising and upgrading the production facilities of the domestic company. Out of the three acquisitions it made within a week in 2006, the integration of Terapia into Ranbaxy was the most difficult process for the management of the Indian group. Ranbaxy signed similar deals in Italy and Belgium, whilst a few months later the Indian group also bought a company in Spain. "I coordinated the whole process of integrating these three companies acquired that week, as well as the integration of the Spanish company into the group. The most difficult process involved Terapia, as in Belgium we had to integrate a product portfolio and a small team, while in Italy, it merely required the integration of the product portfolio," added Peter Burema.
Pentru alte știri, analize, articole și informații din business în timp real urmărește Ziarul Financiar pe WhatsApp Channels
